Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy
| العنوان: | Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy |
|---|---|
| المؤلفون: | Erika Martinelli, Teresa Troiani, Lucia Esposito, Nicola Normanno, Davide Ciardiello, Carmine Pinto, Evaristo Maiello, Chiara Cremolini, Tiziana Latiano, Vincenzo Famiglietti, Giuseppe Santabarbara, Giulia Martini, Antonio Avallone, Stefania Napolitano, Fortunato Ciardiello, Filippo Pietrantonio |
| المساهمون: | Ciardiello, D., Famiglietti, V., Napolitano, S., Esposito, L., Normanno, N., Avallone, A., Latiano, T., Maiello, E., Pietrantonio, F., Cremolini, C., Santabarbara, G., Pinto, C., Troiani, T., Martinelli, E., Ciardiello, F., Martini, G. |
| المصدر: | Cancers Volume 13 Issue 22 Cancers, Vol 13, Iss 5715, p 5715 (2021) |
| بيانات النشر: | MDPI, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Cancer Research, medicine.medical_specialty, Colorectal cancer, medicine.medical_treatment, Gastroenterology, Article, Refractory, Statistical significance, Internal medicine, Medicine, RC254-282, Chemotherapy, Univariate analysis, Cetuximab, business.industry, Hazard ratio, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, skin toxicity, Rechallenge anti‐EGFR, Oncology, mCRC, rechallenge anti-EGFR, Biomarker (medicine), Immunotherapy, MCRC, Skin toxicity, immunotherapy, business, medicine.drug |
| الوصف: | The single-arm phase II CAVE mCRC trial evaluated the combination of cetuximab plus avelumab as rechallenge strategy in RAS wild-type (WT) metastatic colorectal cancer (mCRC) patients, with clinical response to first-line anti-EGFR-based chemotherapy, who progressed and received a subsequent line of therapy. The correlation of skin toxicity (ST) and different clinico-molecular variables with overall survival (OS), progression-free survival (PFS) and response rate (RR) was assessed at univariate and multivariate analysis. A total of 33/77 (42.9%) patients experienced grade 2–3 ST and displayed median OS (mOS) of 17.8 months (CI 95%, 14.9–20.6) whereas 44/77 (57.1%) patients with grade 0–1 ST exhibited mOS of 8.2 months (CI 95%, 5.5–10.9), (hazard ratio (HR), 0.51 CI 95%, 0.29–0.89 p = 0.019). Median PFS (mPFS) was 4.6 months (CI 95%, 3.4–5.7) in patients with grade 2–3 ST, compared to patients with grade 0–1 ST with mPFS of 3.4 months (CI 95%, 2.7–4.1 HR, 0.49 CI 95%, 0.3–0.8 p = 0.004). Grade 2–3 ST (HR, 0.51 p = 0.019) and RAS/BRAF/EGFR WT circulating tumor DNA (ctDNA) (HR, 0.50 CI 95%, 0.27–0.9 p = 0.019) had a statistically significant effect on OS at univariate analysis. At the multivariate analysis, RAS/BRAF/EGFR WT ctDNA status maintained statistical significance (HR, 0.49 p = 0.023), whereas there was a trend towards ST grade 2–3 (HR, 0.54 CI 95%, 0.29–1.01 p = 0.054). Skin toxicity is a promising biomarker to identify patients with mCRC that could benefit of anti-EGFR rechallenge. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2072-6694 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e55445cfc7d6141ad784f6af82ce301bTest http://europepmc.org/articles/PMC8616320Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....e55445cfc7d6141ad784f6af82ce301b |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20726694 |
|---|